Sex-stratified randomized controlled trials (RCTs) in LMICs, OX1R agonists for type 1 diabetes (T1D), and artificial intelligence-guided circadian orexin monitoring to address the $1.1 trillion annual burden (IDF, 2025) are recommended as future priorities. Here, HCRTR1 is linked to type 1 diabetes mellitus.